A Phase 2 interventional study of Delamanid and Bedaquiline in Pulmonary TB, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary — 1 open to participants now, 4 under way, 2 of them phase 3. OPC-67683 · Tuberculosis, Pulmonary.
Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 5th registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →1 of the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary is open now, in 5 countries. Recruiting first, the newest first:
University College, London · Sites in Moldova, South Africa, Tanzania and 2 more countries
Ages 18+
By country, each count listing its studies:
OPC-67683: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 4
First in 2006; this study’s year is marked. 2 started in 2022.
This study's enrollment of 122 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 208 across the 10 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 4 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
3 of the studies testing OPC-67683 in Tuberculosis, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06649721Phase 3Huashan HospitalInnovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort | 2027-02-28 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 26 weeks.
Eligible participants for this study have a diagnosis of pulmonary DS-TB.
This is a Phase 2b/c multicenter, open-label, randomized, dose-finding study, consisting of up to 26 weeks of treatment period.
Following a screening period of up to 14 days, eligible participants will be randomized in the study.
Randomization will be stratified by presence of bilateral cavitation on screening chest x-ray (yes or no). After the end of the treatment period, participants will be followed until 12 months post randomization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, once daily (QD), bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, thrice weekly (TIW) and OPC-167832, 10 mg, oral tablets, QD for a total of 17 weeks.
Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 10 mg
Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, QD, bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, TIW and OPC-167832, 30 mg, oral tablets, QD for a total of 17 weeks.
Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 30 mg
Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, QD, bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, TIW and OPC-167832, 90 mg, oral tablets, QD for a total of 17 weeks.
Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 90 mg
Participants will receive RHEZ, orally, QD for 8 weeks followed by 18 weeks of rifampin and isoniazid for a total of 26 weeks.
Drug: RHEZ · Drug: Rifampin · Drug: Isoniazid
Delamanid (300 mg QD) for 17 weeks
Bedaquiline (400 mg QD x 2 weeks, then 200 mg TIW) for 17 weeks
Drug pages: Rifampin · Isoniazid · Pyrazinamide · Ethambutol
RHEZ (RIFAFOUR single dose combination tablets) for 8 weeks
Also known as: RIFAFOUR
Rifampin tablets for 18 weeks
Isoniazid tablets for 18 weeks
OPC-167832 (10 mg QD) for 17 weeks
OPC-167832 (30 mg QD) for 17 weeks
OPC-167832 (90 mg QD) for 17 weeks
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment. Serious AE are AEs that leads to death, is life threatening, requires or prolongs hospitalization, significant disability, congenital anomaly or birth defect, and other medically important serious advent. AEs were graded on a severity 3-point scale as follows: Mild: Discomfort noticed, but no disruption to daily activity.; Moderate: Discomfort sufficient to reduce or affect normal daily activity.;Severe: Inability to work or perform normal daily activity. As pre-specified in statistical analysis plan (SAP),Division of AIDS (DAIDS v2.1) criteria was used and AEs graded as follows:Grade 1-Mild;Grade 2-Moderate;Grade 3-Severe;Grade 4-Life Threatening;Grade 5-Death.
Time frame: From first dose of study drug up to end of follow up period (up to Week 52)
Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities
Laboratory assessments included clinical chemistry (Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Total Bilirubin, Calcium, Creatinine, estimated Glomerular Filtration Rate (eGFR), Glucose, Fasting and Non-Fasting, Cholesterol, Inorganic Phosphorus, Magnesium, Potassium, Sodium, Triglycerides and Uric Acid), hematology (Activated Partial Thromboplastin Time, Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio (INR), Absolute CD4+ Count, Absolute Lymphocytes, Absolute Neutrophil Count, Hemoglobin, Platelet Count, White Blood Cell), and urinalysis (Urine Glucose, Blood and Protein). As pre-specified in statistical analysis plan (SAP), Division of AIDS (DAIDS) criteria was used and abnormalities were graded as follows:Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death. Laboratory values with DAIDS Grade ≥3 were considered as potentially clinically relevant abnormalities and are reported here.
Time frame: Baseline up to end of follow up period (up to Week 52)
Number of Participants With Potentially Clinically Relevant Abnormalities in the Vital Signs
Vital signs measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body weight, and body temperature. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and sitting positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per DAIDS criteria pre-specified in SAP. Each vital sign parameter was graded using the DAIDS criteria as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Potentially Life Threatening; Grade 5 - Death. The categories with at least one participant with clinically significant value of any grade for vital signs are reported here.
Time frame: Baseline up to end of follow up period (up to Week 52)
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
3 ECGs were performed at baseline (Day -1) spaced 5 to 10 minutes apart, and 3 ECGs at all subsequent visits during the treatment and follow-up periods. The categories with at least one participant with clinically relevant ECG abnormalities are reported here.
Time frame: Baseline up to end of follow up period (up to Week 52)
Number of Participants With an AE Reported as DAIDS Grade 3 or Higher
An AE was defined as any untoward medical occurrence in a clinical trial participant administered a treatment that does not necessarily have a causal relationship with the treatment. All AEs were graded on a 5-point scale according to DAIDS Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death.
Time frame: From first dose of study drug up to end of follow up period (up to approximately Week 52)
Number of Participants With TEAEs Leading to Discontinuation of Treatment
An AE was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment.
Time frame: From first dose of the study drug up to end of follow up period (up to approximately Week 52)
Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17)
A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% confidence interval (CI) was calculated using Clopper Pearson (exact) confidence interval model.
Time frame: Week 17
Percentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26)
A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.
Time frame: Week 26
Percentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment
A participant was classified as having achieved SCC if he/she achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the 8 weeks of treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.
Time frame: Week 8
Time to Detection of MGIT Cultures
Time to detection of MGIT cultures was the time assessed, in days, when a sputum culture result was positive using the MGIT system during the routine 42-day incubation period. A longer time to detection represented a lower burden of mycobacterium tuberculosis (MTB) organisms present in the sputum.
Time frame: Baseline up to Week 52
Percentage of Participants Achieving Negative Sputum Lipoarabinomannan (LAM) by 8 Weeks of Treatment and by End of Treatment
Sputum LAM concentrations were measured on up to 3 samples collected at baseline and postbaseline at Week 8 and at end of treatment. A participant was classified as having achieved negative sputum conversion in LAM if the participant has the first of 2 visits of at least 1 week apart with sputum LAM negative (below the lower limit of quantification) and without a positive sputum LAM result in between. Numeric sputum LAM concentration data was converted to a binary variable using the rule: if the sputum LAM concentration was less than 10 picograms per milliliter (pg/mL) then it was interpreted as a negative result. If the sputum LAM concentration was greater than or equal to 10 pg/mL then it was interpreted as positive result. SCC for LAM was considered to have been achieved if there were negative results at two consecutive visits with non-missing results. 95% CI was calculated using Clopper Pearson (exact) confidence interval model.
Time frame: Week 8, and End of Treatment Period - Week 17 (for OPC-167832 arms) and Week 26 (for RHEZ arm)
Percentage of Participants With Acquired Drug Resistance
Acquired resistance was defined as a post-baseline resistant result at any timepoint after a baseline susceptible result. Baseline was defined as Day -1, if Day -1 was missing then Day 1 was used, if day 1 was missing then Week 1 was used. Resistance data was collected for streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline and delamanid. Susceptibility testing (DST) for anti-TB medications was performed on positive M tuberculosis isolates from Day -1 or Day 1 cultures, and on the end of treatment sputum specimen. Percentage of participants who were susceptible at baseline and developed resistance to the indicated drug (class) at any post-baseline visits was summarized.
Time frame: Baseline up to Week 52
Time to Sputum Culture Conversion (SCC)
Sputum culture conversion occurs when a participant has the first of 2 consecutive visits of at least 7 days apart with sputum cultures negative and without a positive sputum culture result in between, as well as no positive sputum culture after the negative results. If a participant had a positive MGIT culture result throughout the study period, then the participant was considered as not having achieved SCC within the period under consideration. The time to SCC in this case was censored. Time to SCC was calculated from date of first dose using MGIT cultures without the mitigation method measures.
Time frame: From the first dose of the study up to the end of the follow-up period (up to Week 52)
Assess the Positron Emission Tomography/Computerized Axial Tomography (PET/CT) Imaging Response Over the Course of Treatment
Positron emission tomography/computerized axial tomography (PET/CT) imaging changes over the course of treatment, using quantitative scan assessment.
Time frame: Baseline to Week 26
Evaluate the Ribosomal Ribonucleic Acid Synthesis Ratio (RS Ratio) Decline in Sputum
The decline of ribosomal ribonucleic acid synthesis ratio (RS ratio - a ratio of spacers between the mRNA) in sputum over the course of trial.
Time frame: Baseline to 12 months post randomization
Assess Whole Blood Transcriptomic Signatures Previously Associated With TB Cure From Serum
The change in whole blood transcriptomic signatures over the course of treatment will be evaluated using ROC curves for association with microbiological and clinical response.
Time frame: Screening to 12 months post randomization
The Proportion of Participants With Favorable Outcome at 12 Months Post Randomization
The proportion of subjects with favorable outcome as compared to the 6 months post end of treatment and at 12 months post randomization.
Time frame: Baseline to 12 months post randomization
Number of Participants With Relapse at 12 Months Post Randomization
Proportion of participants with relapse at 12 months post randomization.
Time frame: Baseline to 12 months post randomization
Participants took part in the study at 8 clinical sites in South Africa from 12 April 2022 to 19 May 2024.
| Milestone | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Started | 20 | 42 | 39 | 21 |
| Safety analysis set | 20 | 42 | 38 | 21 |
| Modified intent-to-treat (mitt) analysis set | 20 | 42 | 38 | 21 |
| Completed | 20 | 39 | 38 | 21 |
| Not completed | 0 | 3 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Randomized by mistake with trial treatment | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment. Serious AE are AEs that leads to death, is life threatening, requires or prolongs hospitalization, significant disability, congenital anomaly or birth defect, and other medically important serious advent. AEs were graded on a severity 3-point scale as follows: Mild: Discomfort noticed, but no disruption to daily activity.; Moderate: Discomfort sufficient to reduce or affect normal daily activity.;Severe: Inability to work or perform normal daily activity. As pre-specified in statistical analysis plan (SAP),Division of AIDS (DAIDS v2.1) criteria was used and AEs graded as follows:Grade 1-Mild;Grade 2-Moderate;Grade 3-Severe;Grade 4-Life Threatening;Grade 5-Death.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| TEAE | 17 | 37 | 30 | 21 |
| Serious TEAE | 2 | 3 | 0 | 0 |
| Severe TEAE | 3 | 5 | 2 | 1 |
| TEAE Related to Study Drug | 4 | 8 | 5 | 6 |
| TEAE Leading to Study Discontinuation | 0 | 1 | 0 | 0 |
| TEAE Leading to Death | 0 | 1 | 0 | 0 |
| DAIDS Grade 1 TEAE | 4 | 12 | 9 | 8 |
| DAIDS Grade 2 TEAE | 9 | 19 | 17 | 12 |
| DAIDS Grade 3 TEAE | 4 | 4 | 4 | 1 |
| DAIDS Grade 4 TEAE | 0 | 1 | 0 | 0 |
| DAIDS Grade 5 TEAE | 0 | 1 | 0 | 0 |
Laboratory assessments included clinical chemistry (Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Total Bilirubin, Calcium, Creatinine, estimated Glomerular Filtration Rate (eGFR), Glucose, Fasting and Non-Fasting, Cholesterol, Inorganic Phosphorus, Magnesium, Potassium, Sodium, Triglycerides and Uric Acid), hematology (Activated Partial Thromboplastin Time, Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio (INR), Absolute CD4+ Count, Absolute Lymphocytes, Absolute Neutrophil Count, Hemoglobin, Platelet Count, White Blood Cell), and urinalysis (Urine Glucose, Blood and Protein). As pre-specified in statistical analysis plan (SAP), Division of AIDS (DAIDS) criteria was used and abnormalities were graded as follows:Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death. Laboratory values with DAIDS Grade ≥3 were considered as potentially clinically relevant abnormalities and are reported here.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Alanine Aminotransferase (U/L): High: Grade 3 | 0 | 0 | 0 | 1 |
| Aspartate Aminotransferase (U/L): High: Grade 3 | 0 | 1 | 2 | 1 |
| Aspartate Aminotransferase (U/L): High: Grade 4 | 1 | 0 | 1 | 0 |
| Bilirubin (umol/L): High: Grade 3 | 0 | 0 | 1 | 0 |
| Bilirubin (umol/L): High: Grade 4 | 1 | 0 | 0 | 0 |
| Cholesterol (Total) (mmol/L): High: Grade 3 | 0 | 0 | 1 | 0 |
| Creatinine (umol/L): High: Grade 3 | 3 | 3 | 5 | 1 |
| eGFR (mL/min): Low: Grade 3 | 2 | 6 | 8 | 0 |
| Glucose (Non-Fasting) (mmol/L): High: Grade 3 | 0 | 3 | 1 | 0 |
| Glucose (Non-Fasting) (mmol/L): High: Grade 4 | 0 | 0 | 0 | 0 |
| Potassium (mmol/L): High: Grade 4 | 0 | 1 | 0 | 0 |
| Sodium (mmol/L): High: Grade 3 | 0 | 1 | 0 | 0 |
| Triglycerides (mmol/L): High Grade 3 | 0 | 0 | 1 | 0 |
| Hemoglobin (g/dL): All (Males or Females): Low: Grade 3 | 1 | 2 | 2 | 0 |
| Hemoglobin (g/dL): All (Males or Females): Low: Grade 4 | 0 | 1 | 0 | 0 |
| Lymphocytes (x10^9/L): Low: Grade 3 | 0 | 0 | 1 | 0 |
| Prothrombin Time (sec): High: Grade 3 | 0 | 1 | 0 | 0 |
| Urine Protein: Grade 3 | 0 | 2 | 0 | 0 |
Vital signs measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body weight, and body temperature. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and sitting positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per DAIDS criteria pre-specified in SAP. Each vital sign parameter was graded using the DAIDS criteria as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Potentially Life Threatening; Grade 5 - Death. The categories with at least one participant with clinically significant value of any grade for vital signs are reported here.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Hypertension- DBP: Grade 1 | 8 | 8 | 13 | 8 |
| Hypertension- DBP: Grade 2 | 2 | 4 | 3 | 1 |
| Hypertension- DBP: Grade 3 | 1 | 2 | 1 | 1 |
| Hypertension- SBP: Grade 1 | 8 | 10 | 16 | 8 |
| Hypertension- SBP: Grade 2 | 3 | 2 | 2 | 2 |
| Hypertension- SBP: Grade 3 | 1 | 0 | 1 | 0 |
| Body Temperature Increased: Grade 1 | 1 | 3 | 2 | 2 |
| Body Temperature Increased: Grade 2 | 0 | 3 | 3 | 2 |
| Body Temperature Increased: Grade 3 | 0 | 0 | 0 | 1 |
| Body Temperature Increased: Grade 4 | 0 | 0 | 1 | 0 |
| Body Weight Decreased: Grade 2 weight loss from baseline | 4 | 5 | 4 | 1 |
| Body Weight Decreased: Grade 3 body weight loss from baseline | 1 | 0 | 0 | 1 |
3 ECGs were performed at baseline (Day -1) spaced 5 to 10 minutes apart, and 3 ECGs at all subsequent visits during the treatment and follow-up periods. The categories with at least one participant with clinically relevant ECG abnormalities are reported here.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| First Degree AV Block: > 200 msec | 1 | 6 | 3 | 0 |
| Increase in QT: >450 msec | 4 | 7 | 3 | 2 |
| Increase in QT: >480 msec | 2 | 0 | 0 | 0 |
| Increase in QTcB: >450 msec | 5 | 15 | 7 | 3 |
| Increase in QTcB: >480 msec | 2 | 4 | 0 | 0 |
| Increase in QTcB: >60 Increase from baseline | 0 | 2 | 1 | 0 |
| Increase in QTcB: >=30 to <=60 Increase from baseline | 6 | 20 | 13 | 5 |
| Increase in QTcF: >450 msec | 5 | 8 | 4 | 1 |
| Increase in QTcF: >60 Increase from baseline | 0 | 5 | 2 | 1 |
| Increase in QTcF: >=30 to <=60 Increase from baseline | 13 | 28 | 27 | 11 |
| RR High: > 1200 msec | 6 | 7 | 6 | 3 |
| RR Low: < 600 msec | 1 | 4 | 5 | 6 |
| Sinus Bradycardia: Heart Rate {HR} _Mean < 41 beats per minute {bpm} | 0 | 1 | 0 | 0 |
| Sinus Bradycardia: HR_Mean < 50 bpm | 5 | 7 | 5 | 3 |
| Sinus Tachycardia: HR_Mean > 100 bpm | 4 | 4 | 5 | 6 |
An AE was defined as any untoward medical occurrence in a clinical trial participant administered a treatment that does not necessarily have a causal relationship with the treatment. All AEs were graded on a 5-point scale according to DAIDS Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Number of Participants With an AE Reported as DAIDS Grade 3 or Higher | 4 | 6 | 4 | 1 |
An AE was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment.
| Participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Discontinuation of Treatment | 0 | 1 | 0 | 0 |
A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% confidence interval (CI) was calculated using Clopper Pearson (exact) confidence interval model.
| percentage of participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17) | 100.0 (83.2 to 100.0) | 92.9 (80.5 to 98.5) | 97.4 (86.2 to 99.9) |
A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.
| percentage of participants | RHEZ |
|---|---|
| Percentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26) | 100.0 (83.9 to 100.0) |
A participant was classified as having achieved SCC if he/she achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the 8 weeks of treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.
| percentage of participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Percentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment | 40.0 (19.1 to 63.9) | 57.1 (41.0 to 72.3) | 50.0 (33.4 to 66.6) | 52.4 (29.8 to 74.3) |
Time to detection of MGIT cultures was the time assessed, in days, when a sputum culture result was positive using the MGIT system during the routine 42-day incubation period. A longer time to detection represented a lower burden of mycobacterium tuberculosis (MTB) organisms present in the sputum.
| days | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Baseline | 5.7 (4 to 15) | 5.1 (3 to 42) | 5.3 (2 to 29) | 5.5 (4 to 12) |
| Week 1 | 8.5 (3 to 42) | 8.8 (5 to 16) | 10.4 (4 to 42) | 9.3 (6 to 17) |
| Week 2 | 9.9 (7 to 42) | 10.5 (5 to 42) | 11.9 (4 to 42) | 12.0 (6 to 42) |
| Week 3 | 12.6 (8 to 42) | 12.6 (5 to 42) | 15.5 (9 to 42) | 14.0 (8 to 42) |
| Week 4 | 12.6 (8 to 42) | 14.4 (4 to 42) | 18.1 (6 to 42) | 15.9 (9 to 42) |
| Week 5 | 19.3 (9 to 42) | 18.6 (9 to 42) | 21.9 (6 to 42) | 21.7 (11 to 42) |
| Week 6 | 19.0 (11 to 42) | 23.0 (9 to 42) | 22.9 (11 to 42) | 23.6 (11 to 42) |
| Week 7 | 20.1 (8 to 42) | 28.6 (11 to 42) | 32.6 (12 to 42) | 30.6 (13 to 42) |
| Week 8 | 35.2 (10 to 42) | 42.0 (11 to 42) | 42.0 (11 to 42) | 42.0 (7 to 42) |
| Week 10 | 42.0 (13 to 42) | 42.0 (12 to 42) | 42.0 (4 to 42) | 42.0 (17 to 42) |
| Week 12 | 42.0 (17 to 42) | 42.0 (16 to 42) | 42.0 (8 to 42) | 42.0 (24 to 42) |
| Week 13 | 42.0 (42 to 42) | 42.0 (14 to 42) | 42.0 (18 to 42) | 42.0 (30 to 42) |
| Week 15 | 42.0 (11 to 42) | 42.0 (15 to 42) | 42.0 (18 to 42) | 42.0 (36 to 42) |
| Week 17 | 42.0 (42 to 42) | 42.0 (29 to 42) | 42.0 (17 to 42) | 42.0 (42 to 42) |
| Week 19 | 42.0 (4 to 42) | 42.0 (42 to 42) | 42.0 (24 to 42) | 42.0 (42 to 42) |
| Week 21 | 42.0 (42 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) |
| Week 23 | 42.0 (18 to 42) | 42.0 (42 to 42) | 42.0 (28 to 42) | 42.0 (42 to 42) |
| Week 26 | 42.0 (9 to 42) | 42.0 (42 to 42) | 42.0 (6 to 42) | 42.0 (42 to 42) |
| Week 28 | 42.0 (14 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) |
| Week 30 | 42.0 (23 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) | 42.0 (42 to 42) |
| Week 34 | 42.0 (42 to 42) | 42.0 (12 to 42) | 42.0 (19 to 42) | 42.0 (16 to 42) |
| Week 39 | 42.0 (42 to 42) | 42.0 (7 to 42) | 42.0 (14 to 42) | 42.0 (3 to 42) |
| Week 43 | 42.0 (7 to 42) | 42.0 (4 to 42) | 42.0 (7 to 42) | 42.0 (19 to 42) |
| Week 47 | 42.0 (7 to 42) | 42.0 (4 to 42) | 42.0 (16 to 42) | 42.0 (10 to 42) |
| Week 52 | 42.0 (13 to 42) | 42.0 (13 to 42) | 42.0 (18 to 42) | 42.0 (42 to 42) |
| Early Termination | — | 11.0 (11 to 11) | — | — |
Sputum LAM concentrations were measured on up to 3 samples collected at baseline and postbaseline at Week 8 and at end of treatment. A participant was classified as having achieved negative sputum conversion in LAM if the participant has the first of 2 visits of at least 1 week apart with sputum LAM negative (below the lower limit of quantification) and without a positive sputum LAM result in between. Numeric sputum LAM concentration data was converted to a binary variable using the rule: if the sputum LAM concentration was less than 10 picograms per milliliter (pg/mL) then it was interpreted as a negative result. If the sputum LAM concentration was greater than or equal to 10 pg/mL then it was interpreted as positive result. SCC for LAM was considered to have been achieved if there were negative results at two consecutive visits with non-missing results. 95% CI was calculated using Clopper Pearson (exact) confidence interval model.
| percentage of participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| At Week 8 | 0 (0 to 0) | 2.4 (0.1 to 12.6) | 0 (0 to 0) | 14.3 (3.0 to 36.3) |
| At End of Treatment - Week 17 and Week 26 | 15.0 (3.2 to 37.9) | 14.3 (5.4 to 28.5) | 23.7 (11.4 to 40.2) | 23.8 (8.2 to 47.2) |
Acquired resistance was defined as a post-baseline resistant result at any timepoint after a baseline susceptible result. Baseline was defined as Day -1, if Day -1 was missing then Day 1 was used, if day 1 was missing then Week 1 was used. Resistance data was collected for streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline and delamanid. Susceptibility testing (DST) for anti-TB medications was performed on positive M tuberculosis isolates from Day -1 or Day 1 cultures, and on the end of treatment sputum specimen. Percentage of participants who were susceptible at baseline and developed resistance to the indicated drug (class) at any post-baseline visits was summarized.
| percentage of participants | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Percentage of Participants With Acquired Drug Resistance | 0 | 0 | 0 | 0 |
Sputum culture conversion occurs when a participant has the first of 2 consecutive visits of at least 7 days apart with sputum cultures negative and without a positive sputum culture result in between, as well as no positive sputum culture after the negative results. If a participant had a positive MGIT culture result throughout the study period, then the participant was considered as not having achieved SCC within the period under consideration. The time to SCC in this case was censored. Time to SCC was calculated from date of first dose using MGIT cultures without the mitigation method measures.
| days | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Time to Sputum Culture Conversion (SCC) | 70.0 (51.0 to 84.5) | 56.0 (49.0 to 84.0) | 69.5 (49.0 to 84.0) | 56.0 (48.0 to 71.0) |
Positron emission tomography/computerized axial tomography (PET/CT) imaging changes over the course of treatment, using quantitative scan assessment.
Results for this outcome have not been posted.
The decline of ribosomal ribonucleic acid synthesis ratio (RS ratio - a ratio of spacers between the mRNA) in sputum over the course of trial.
Results for this outcome have not been posted.
The change in whole blood transcriptomic signatures over the course of treatment will be evaluated using ROC curves for association with microbiological and clinical response.
Results for this outcome have not been posted.
The proportion of subjects with favorable outcome as compared to the 6 months post end of treatment and at 12 months post randomization.
Results for this outcome have not been posted.
Proportion of participants with relapse at 12 months post randomization.
Results for this outcome have not been posted.
Collected over From first dose of the study drug up to end of follow up period (up to Week 52). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delamanid + Bedaquiline + OPC-167832 10 mg | 0/20 (0%) | 2/20 (10%) | 17/20 (85%) |
| Delamanid + Bedaquiline + OPC-167832 30 mg | 1/42 (2.4%) | 3/42 (7.1%) | 31/42 (73.8%) |
| Delamanid + Bedaquiline + OPC-167832 90 mg | 0/38 (0%) | 0/38 (0%) | 25/38 (65.8%) |
| RHEZ | 0/21 (0%) | 0/21 (0%) | 20/21 (95.2%) |
| Event | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Appendicitis perforatedInfections and infestations | 1/20 | 0/42 | 0/38 | 0/21 |
| Localised infectionInfections and infestations | 1/20 | 0/42 | 0/38 | 0/21 |
| PneumoniaInfections and infestations | 0/20 | 1/42 | 0/38 | 0/21 |
| TuberculosisInfections and infestations | 0/20 | 1/42 | 0/38 | 0/21 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/20 | 1/42 | 0/38 | 0/21 |
| MyelopathyNervous system disorders | 0/20 | 1/42 | 0/38 | 0/21 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/20 | 1/42 | 0/38 | 0/21 |
| Event | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/20 | 13/42 | 12/38 | 8/21 |
| HeadacheNervous system disorders | 3/20 | 8/42 | 7/38 | 6/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/20 | 2/42 | 0/38 | 4/21 |
| DiarrhoeaGastrointestinal disorders | 2/20 | 5/42 | 2/38 | 3/21 |
| NauseaGastrointestinal disorders | 0/20 | 0/42 | 3/38 | 3/21 |
| Lower respiratory tract infectionInfections and infestations | 2/20 | 0/42 | 2/38 | 3/21 |
| Back painMusculoskeletal and connective tissue disorders | 2/20 | 5/42 | 2/38 | 0/21 |
| Abdominal painGastrointestinal disorders | 2/20 | 1/42 | 1/38 | 1/21 |
| Electrocardiogram QT prolongedInvestigations | 2/20 | 2/42 | 0/38 | 0/21 |
| Abnormal loss of weightMetabolism and nutrition disorders | 2/20 | 0/42 | 0/38 | 0/21 |
The randomized analysis set included all participants who were randomized into the trial.
| Age, Continuous(years) | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ | Total |
|---|---|---|---|---|---|
| Mean | 37.7 ± 11.90 | 32.8 ± 11.92 | 33.2 ± 12.13 | 32.7 ± 9.91 | 33.7 ± 11.66 |
| Sex: Female, Male(Participants) | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ | Total |
|---|---|---|---|---|---|
| Female | 6 | 15 | 13 | 9 | 43 |
| Male | 14 | 27 | 26 | 12 | 79 |
| Race/Ethnicity, Customized(Participants) | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ | Total |
|---|---|---|---|---|---|
| Race — Black or African American | 13 | 27 | 29 | 14 | 83 |
| Race — Other | 7 | 15 | 10 | 7 | 39 |
| Race/Ethnicity, Customized(Participants) | Delamanid + Bedaquiline + OPC-167832 10 mg | Delamanid + Bedaquiline + OPC-167832 30 mg | Delamanid + Bedaquiline + OPC-167832 90 mg | RHEZ | Total |
|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Ethnicity — Not Hispanic or Latino | 20 | 42 | 39 | 21 | 122 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Apr 2022 to primary completion in Apr 2024, 23 months.
Results were first posted in Aug 2026, 2 years 4 months after primary completion. A results delay was requested in Apr 2025.
Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: OPC-67683 · Bedaquiline · Quabodepistat
Otsuka Pharmaceutical Development & Commercialization, Inc. →